Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: ACAD stock price vs KKR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at KKR's multiple
Needs KKR P/E.
Implied fair value · at ACAD's multiple
Needs ACAD P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ACAD FY 2025 (ended Dec 31, 2025) · KKR FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ACADIA PHARMACEUTICALS INC. · implied price per share
Bear
$5.79
Base
$6.81
Bull
$7.83
KKR & CO. INC. · implied price per share
Bear
$45.27
Base
$53.26
Bull
$61.24
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.00x
1.08x
Net debt / EBITDA
Leverage against operating earnings
-1.51x
3.20x
Cash and equivalents
Liquid reserves on the balance sheet
$227.76M
$5.36B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ACAD vs SUPN
Sage Therapeutics, Inc.
ACAD vs SAGE
Jazz Pharmaceuticals plc
ACAD vs JAZZ
Alkermes plc.
ACAD vs ALKS
Harmony Biosciences Holdings, Inc.
ACAD vs HRMY
Krystal Biotech, Inc.
ACAD vs KRYS
BlackRock, Inc.
ACAD vs BLK
Blackstone Inc.
ACAD vs BX
Apollo Global Management, Inc.
ACAD vs APO
Carlyle Group Inc.
ACAD vs CG
Ares Management Corp
ACAD vs ARES
$32.00K
$33.42B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
